US giants face off in biggest biosimilar battle yet

21 September 2017

The share price of the world’s biggest pharma company Pfizer (NYSE: PFE) closed 1.5% up on Wednesday while that of Johnson & Johnson (NYSE: JNJ), the globe’s largest healthcare firm, decreased by the same percentage.

Markets were reacting to news that Pfizer had filed a lawsuit against the fellow US firm, accusing it of using exclusionary contracts and other anticompetitive practices to maintain its monopoly in connection with the anti-inflammatory drug Remicade (infliximab).

J&J, which earned nearly $10 billion last year from Remicade – making it the group’s top-selling pharma product – has said there is ‘no merit in this lawsuit’.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK